NBTXR3 Activated by Radiotherapy for Patients With Advanced Cancers Treated With An Anti-PD-1 Therapy
Status:
Recruiting
Trial end date:
2023-03-30
Target enrollment:
Participant gender:
Summary
The 1100 study is an open-label, Phase I, prospective clinical study to assess the safety of
intratumoral injection of NBTXR3 activated by radiotherapy in combination with anti-PD-1
therapy.